ArticleFrontiers in toxicology2026
Transcriptomic and functional profiling of endothelial dysfunction induced by polystyrene nanoplastics.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The presence of micro- and nanoplastics (MNPLs) in human blood raises concerns about their vascular impact and their potential contribution to cardiovascular diseases. Endothelial cells are a primary target of circulating MNPLs; however, the molecular and functional consequences of this exposure remain largely undefined. Methods: In this study, we exposed primary human umbilical vein endothelial cells (HUVECs) to carboxylated polystyrene nanoplastics (PS-NPLs; 30, 50, and 100 nm) and integrated RNA sequencing with targeted functional assays. Results: Transcriptomics revealed a robust response characterized by coordinated dysregulation of cholesterol homeostasis, genotoxic stress and DNA repair, inflammatory signaling, and endothelial plasticity (endothelial-to-mesenchymal transition). Guided by these signatures, functional assays confirmed increased intracellular cholesterol, DNA damage, remodelling of migratory capacity and angiogenic behaviour, and reduced IL-6 secretion. Discussion: Overall, the concordance between transcriptomic programs and functional endpoints supports a mechanistic framework in which PS-NPL exposure rewires endothelial metabolic and stress-response networks, with downstream consequences for key vascular functions. Differences across the nanoscale range modulated the magnitude and temporal profile of specific endpoints, but the shared molecular core response predominated across treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.